News & Events

26 03, 2025

Orthogonal Host-Guest Interactions Enable Programming of Protocell Membranes for Cellular High-Order Assembly and Enhanced Immunogenicity

2025-03-26T00:00:00+00:00

The complement system's distinguishing feature is its cell-specific surface ligands. However, the limited scalability and complexity of incorporating surface-customizable ligands into membrane-bound cell-like microassemblages have hindered their widespread adoption in synthetic biology and bioengineering. Here, we present a method for the batch construction of polysaccharide-based microcapsules (polysaccharidosomes, P-somes) with intrinsic functional host membranes capable of [...]

Orthogonal Host-Guest Interactions Enable Programming of Protocell Membranes for Cellular High-Order Assembly and Enhanced Immunogenicity2025-03-26T00:00:00+00:00
19 03, 2025

Cell-Based Relative Potency of a Respiratory Syncytial Virus mRNA Vaccine Correlates with In Vivo Immunogenicity

2025-12-22T20:36:06+00:00

Background/Objectives: Potency is a critical quality attribute for vaccine development as well as clinical drug product (DP) lot release and stability testing. Animal studies have the potential to offer conclusive insights about the potency of vaccines by demonstrating technical relevance with respect to the hypothesized vaccine mode of action. However, animal studies are expensive, time-consuming, [...]

Cell-Based Relative Potency of a Respiratory Syncytial Virus mRNA Vaccine Correlates with In Vivo Immunogenicity2025-12-22T20:36:06+00:00
18 03, 2025

Empowering Drug Development with CLIA Testing Services

2025-12-23T22:00:38+00:00

Avance Biosciences offers CLIA-compliant testing services to ensure accurate, reliable data throughout drug development. From biomarker validation to regulatory support, our expertise helps biopharmaceutical companies advance clinical trials and bring innovative biologic treatments to market with confidence...

Empowering Drug Development with CLIA Testing Services2025-12-23T22:00:38+00:00
11 03, 2025

Breakthrough in Genetic Medicine: Beam Therapeutics Shows Potential with BEAM-302 for Alpha-1 Antitrypsin Deficiency

2025-12-23T18:34:16+00:00

Beam Therapeutics announces groundbreaking results from its Phase 1/2 trial of BEAM-302, demonstrating the first-ever clinical genetic correction for Alpha-1 Antitrypsin Deficiency (AATD), offering hope for a potential one-time cure for this genetic disorder...

Breakthrough in Genetic Medicine: Beam Therapeutics Shows Potential with BEAM-302 for Alpha-1 Antitrypsin Deficiency2025-12-23T18:34:16+00:00
4 03, 2025

New RNA-Guided System Uncovered, Offering Promise for Precision Gene Editing Therapies

2025-12-23T18:34:28+00:00

TIGR (Tandem Interspaced Guide RNA) systems use RNA guides to target specific DNA sites, offering a compact and modular alternative to CRISPR. Scientists at MIT and the Broad Institute discovered over 20,000 TIGR-associated proteins, some capable of precise DNA cutting, potentially expanding genome...

New RNA-Guided System Uncovered, Offering Promise for Precision Gene Editing Therapies2025-12-23T18:34:28+00:00
1 03, 2025

Photoresponsive Bio-Heterojunctions Eliciting Immunogenicity to Prevent Infection Recurrence and Accelerating Chronic Wound Regeneration

2025-03-01T00:00:00+00:00

Dynamic therapy utilizes reactive oxygen species (ROS) to antibacterial and enhance the innate immune system to treat bacterial infections. If ROS levels are too low, the elimination of pathogens and the enhancement of innate immunity cannot be achieved. However, excess accumulation of ROS may impact intracellular glutathione (GSH) levels, hindering T cell maturation and the [...]

Photoresponsive Bio-Heterojunctions Eliciting Immunogenicity to Prevent Infection Recurrence and Accelerating Chronic Wound Regeneration2025-03-01T00:00:00+00:00
1 03, 2025

Assessing the effect of beta-propiolactone inactivation on the antigenicity and immunogenicity of cluster 2.1 duck Tembusu virus

2025-03-01T00:00:00+00:00

Duck Tembusu virus (DTMUV), an emerging avian pathogenic flavivirus, causes severe neurological disorders and acute egg drop syndrome in ducks. Currently, several clusters of DTMUV exhibiting significant antigenic variation are circulating in Asia with distinct geographical distributions. Therefore, developing vaccines based on virus clusters specific to regions is essential. To generate an effective inactivated vaccine, [...]

Assessing the effect of beta-propiolactone inactivation on the antigenicity and immunogenicity of cluster 2.1 duck Tembusu virus2025-03-01T00:00:00+00:00
1 03, 2025

The changes necessary in the assessment of immunogenicity for the development of Biosimilars

2025-03-01T00:00:00+00:00

Immunogenicity knowledge and the analytical capabilities to characterize molecules have evolved within the last decade. This creates opportunities in Biosimilar development by applying new strategies to demonstrate similarity between a proposed Biosimilar to its Reference.Within Immunogenicity Risk Assessment for Biosimilars, in silico and in vitro immunogenicity assessment tools are being evaluated for their utility in [...]

The changes necessary in the assessment of immunogenicity for the development of Biosimilars2025-03-01T00:00:00+00:00
26 02, 2025

Avance Biosciences™ Registers with CLIA, Expanding Clinical Trial Testing Capabilities

2025-12-23T18:34:42+00:00

HOUSTON, Feb. 26, 2025 /PRNewswire/ -- Avance Biosciences, a leading provider of high-quality analytical and bioanalytical services for the pharmaceutical industry, is pleased to announce that it has successfully registered with the Clinical Laboratory Improvement Amendments (CLIA) program. This registration allows Avance Biosciences to operate under its assigned CLIA number and offer high-complexity laboratory testing [...]

Avance Biosciences™ Registers with CLIA, Expanding Clinical Trial Testing Capabilities2025-12-23T18:34:42+00:00
26 02, 2025

Gene Therapy Restores Vision in Children with AIPL1-Related Retinal Dystrophy

2025-12-23T18:34:55+00:00

A groundbreaking gene therapy using rAAV8.hRKp.AIPL1 has restored vision in 11 children with AIPL1-related retinal dystrophy (LCA4), who were blind at birth. Published in The Lancet, the study shows significant improvements in visual acuity and retinal preservation, supporting expedited approval...

Gene Therapy Restores Vision in Children with AIPL1-Related Retinal Dystrophy2025-12-23T18:34:55+00:00
Go to Top